You are here

  • Home
  • Archive
  • Volume 63, Issue 3
  • Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality

Article info

Article menu
Download PDFPDF
Hepatology
Original article
Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality

Authors

  • Chun-Jen Liu Department of Internal Medicine, Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan, Republic of China Graduate Institute of Clinical Medicine, Collage of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China PubMed articlesGoogle scholar articles
  • Yu-Tseng Chu Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China Center of Comparative Effectiveness Research, Clinical Trial Center, National Taiwan University Hospital, Taipei, Taiwan, Republic of China PubMed articlesGoogle scholar articles
  • Wen-Yi Shau Graduate Institute of Clinical Medicine, Collage of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China PubMed articlesGoogle scholar articles
  • Raymond N Kuo Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China Center of Comparative Effectiveness Research, Clinical Trial Center, National Taiwan University Hospital, Taipei, Taiwan, Republic of China PubMed articlesGoogle scholar articles
  • Pei-Jer Chen Department of Internal Medicine, Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan, Republic of China Graduate Institute of Clinical Medicine, Collage of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China PubMed articlesGoogle scholar articles
  • Mei-Shu Lai Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China Center of Comparative Effectiveness Research, Clinical Trial Center, National Taiwan University Hospital, Taipei, Taiwan, Republic of China Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Mei-Shu Lai, Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, 5F. No. 17, Hsu Chow Road, Taipei, Taiwan 10055, Republic of China; mslai{at}cph.ntu.edu.tw Dr Pei-Jer Chen, Department of Internal Medicine and Hepatitis Research Center, National Taiwan University Hospital, Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, 1 Chang-Te Street, Taipei, Taiwan 10002, Republic of China; peijerchen{at}ntu.edu.tw
View Full Text

Citation

Liu C, Chu Y, Shau W, et al
Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality
Gut 2014;63:506-514.

Publication history

  • Received December 22, 2012
  • Revised April 12, 2013
  • Accepted April 15, 2013
  • First published May 15, 2013.
Online issue publication 
February 04, 2014

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions